论文部分内容阅读
目的:研究恩替卡韦联合微生态制剂对乙肝肝硬化患者肠粘膜屏障功能及肝功能的影响。方法:选取2010年4月至2013年5月于本院治疗的乙肝肝硬化患者150例,根据治疗方式不同将其分为观察组(恩替卡韦联合微生态制剂)和对照组(恩替卡韦),各75例。对比两组患者肠粘膜屏障功能、肝功能变化以及不良反应发生情况。结果:治疗后,两组患者AST、TBIL指标均较治疗前下降,且观察组低于对照组,差异有统计学意义(P<0.05);两组均无严重不良反应发生。结论:恩替卡韦联合微生态制剂可有效改善患者的肠粘膜屏障功能和肝功能,用药安全性较高。
Objective: To study the effect of entecavir combined with probiotics on intestinal mucosal barrier function and liver function in patients with hepatitis B cirrhosis. Methods: One hundred and fifty patients with hepatitis B cirrhosis who were treated in our hospital from April 2010 to May 2013 were divided into observation group (entecavir combined with probiotics) and control group (entecavir) according to the different treatment methods, each 75 example. Comparing the two groups of patients with intestinal mucosal barrier function, changes in liver function and adverse reactions. Results: After treatment, the indexes of AST and TBIL in both groups decreased compared with before treatment, and the observation group was lower than the control group, the difference was statistically significant (P <0.05). No serious adverse reactions occurred in both groups. Conclusion: Entecavir combined with probiotics can effectively improve intestinal mucosal barrier function and liver function in patients with high safety.